In support of improving patient care, Idaho State University Kasiska Division of Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Disclosure Statement

• The planners and presenter of this presentation have disclosed no conflict of interest, including no relevant financial relationships with any commercial interests
Objectives

• Utilize helpful tools and materials to assist in medication deprescribing

• Select common medications for deprescribing in individual patients

• Implement an appropriate strategy for safe discontinuation of common medications
DEPRESCRIBING OVERVIEW
Defining Deprescribing

• “Systematic process of identifying and discontinuing drugs in instances in which existing or potential harms outweigh existing or potential benefits within the context of an individual patient’s care goals, current level of functioning, life expectancy, values and preferences.”
  - Scott IA, et al.

• “The process of withdrawal of an inappropriate medication, supervised by a health care professional with the goal of managing polypharmacy and improving outcomes”
  - Reeve E, et al.

Deprescribing Process

1. Obtain a complete medication list with indications for each medication
2. Assess each medication for the risk of drug-induced harm
3. Evaluate the appropriateness of each medication
4. Prioritize drugs for discontinuation
5. Implement a discontinuation plan and monitor the patient’s progress

Deprescribing Algorithm

1. **No benefit** - Significant toxicity, no indication, obvious contraindication, cascade prescribing?
   - Yes
   - No

2. **Harm outweighs benefit** - Adverse effects outweigh symptomatic effect or potential future benefits?
   - Yes
   - No

3. **Symptom or disease drug** - Symptoms stable or nonexistent?
   - Yes
   - No

4. **Preventive drugs** - Potential benefit unlikely to be realized because of limited life expectancy?
   - Yes
   - No

- **Withdrawal symptoms or disease recurrence likely if drug therapy discontinued?**
  - Yes
  - No

- Taper dose and monitor for adverse drug withdrawal effects

- **Symptoms stable or nonexistent?**
  - Yes
  - No

- Continue drug therapy

- Discontinue drug therapy

- Restart drug therapy

Safety Concerns of Deprescribing

- Adverse drug withdrawal events
  - Physiological reactions to withdrawal
  - Associated with corticosteroids, CNS agents and PPIs
  - Can be prevented by tapering but could still occur during the taper
  - Serious harm is rare

Safety Concerns of Deprescribing

• Return of medical condition
  – Prevalence of return varies between conditions
  – Close monitoring can minimize the consequences
  – Restarting the discontinued medication can revert symptoms to baseline
  – Deprescribing preventative medications can be more challenging due to difficulty in monitoring
    • Difficult to know if breaks in therapy will have long term effects

Safety Concerns of Deprescribing

• Reversal of drug-drug interactions
  – Limited research in this area
  – Consider pharmacokinetic and pharmacodynamic implications of drugs being discontinued
    • Enzyme inducers or inhibitors
    • Effects on drugs with narrow therapeutic indexes

Barriers to Deprescribing

• Provider Barriers
  – Concern about contradicting a specialist’s recommendation
  – Fear of causing withdrawal symptoms or disease relapse
  – Lack of data to assess risks and benefits with older patients
  – Worry that discussing life expectancy and deprescribing may be interpreted as a reduction in care
  – Pressure from guideline recommendations
  – Limited time to discuss discontinuation

• Addressing Barriers
  – Work as a team to develop a collaborative, patient-centered plan
  – Clearly communicate with all providers involved in the patient’s care
    • Include patient-specific factors and evidence-based risk/benefit assessments to support deprescribing decisions
    • When available, use evidence-based deprescribing guidelines and algorithms

Barriers to Deprescribing

• Patient Barriers
  – Fear of the condition worsening or returning
  – Previous negative experience with deprescribing
  – Influence from friends, family, etc.
  – Hope of future effectiveness

• Addressing Barriers
  – Include the patient and caregivers in the process
    • Shared decision making
  – Provide education about risks and benefits
  – Provide a clear plan that includes managing withdrawal symptoms
  – Provide ongoing support and monitoring to reassure the patient and caregivers

Deprescribing Through Shared Decision Making

• Step 1: Creating awareness that options exist

• Step 2: Discussing the options and their benefits and harms

• Step 3: Exploring patient preferences for the different options

• Step 4: Making the decision

DEPRESCRIBING TOOLS
Beers Criteria

• Lists of potentially inappropriate medications for older patients

• Lists of medications that should be avoided or adjusted based on kidney function and drug-drug interactions

• Does not include suggestions for how to discontinue medications

STOPP/START Criteria

- Screening Tool for Older People’s Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment (START)

- Screening tool for older patients to identify potentially inappropriate (STOPP) and appropriate (START) medications

- Does not include suggestions for how to discontinue medications

Deprescribing.org

- Deprescribing algorithms and guidelines for PPIs, benzodiazepines, antipsychotics and antihyperglycemics

- Deprescribing information pamphlets and patient decision aids

- Links to additional resources
Medstopper.com

• Tool for identifying medications to reduce or discontinue

• Provides a stopping priority for each of the patients medications
  – Cites Beers and STOPP criteria when applicable

• Includes recommendations for suggested tapers and symptoms to watch for when discontinuing medications

• Some medications have links to patient decision tools for calculating risks and benefits
Primary Health Tasmania

• Primary Health Tasmania Website

• Deprescribing guides and fact sheets for several drug classes
  – Sulfonylureas, statins, PPIs, opioids, NSAIDs, glaucoma eye drops, cholinesterase inhibitors, bisphosphonates, benzodiazepines, antipsychotics, antiplatelet agents, antihypertensive agents, allopurinol, and vitamin D & calcium.

• Deprescribing Quick Reference Guide for all drug classes covered

• Fact sheets discuss risks and benefits of the medication class as well as strategies for limiting discontinuation syndromes
A Practical Guide to Stopping Medications in Older People

• Available at:  

• Overview of general deprescribing concepts

• Specific guidance on stopping several common medications  
  – Includes tapers and withdrawal effects (when applicable)  
  – Antidepressants, benzodiazepines, antihypertensive, statins, warfarin, NSAIDs, acid suppressants, oral corticosteroids, antiparkinsonian medications and bisphosphonates

• Does not discuss risks and benefits
DEPRESCRIBING COMMON MEDICATIONS
ANTIPSYCHOTICS
Antipsychotics: Why Deprescribe?

- Limited evidence to support use in patients with dementia
- Limited evidence for treating insomnia in patients without psychosis
- Increased risk of cardiovascular, metabolic and cognitive adverse effects


Antipsychotics: How to deprescribe?

- Decrease dose by 25-50% every 1-2 weeks over 3-6 months in patients with dementia.

- If taking for insomnia (usually low doses), can stop without taper.

- Monitor every 1-2 weeks for return of neuro-psychiatric symptoms.

- If symptoms return:
  - Attempt behavioral interventions
  - Restart at lowest dose possible and try deprescribing again in 3 months (2 attempts should be made)
  - Consider change to risperidone, olanzapine, aripiprazole


BENZODIAZEPINES
Benzodiazepines: Why Deprescribe?

• Can cause confusion and increase risk of falls

• Not indicated for treatment of insomnia

• Discontinuation can improve cognition and psychomotor abilities

Benzodiazepines: How to deprescribe?

• Decrease by 25% every 2 weeks then 12.5% reductions near the end of the taper if possible or drug planned drug-free days

• Provide education and recommend supportive strategies
  – Behavior change strategies
  – Talk therapy

• Monitor every 1-2 weeks for duration of taper

• If symptoms relapse:
  – Continue current dose for 1-2 weeks then resume taper at a slower rate
  – Recommend alternative medications for insomnia

CHOLINESTERASE INHIBITORS
Cholinesterase Inhibitors: Why Deprescribe?

• Only indicated for mild to moderate Alzheimer’s disease
  – Minimal benefit in patients with severe dementia

• Used to slow progression and provide symptomatic relief
  – Do not stop or reverse progression

• Can cause abdominal pain, anorexia, diarrhea, nausea, vomiting, and weight loss

Cholinesterase Inhibitors: Candidates for deprescribing

- Patients who:
  - Do not improve within 3 months of initiating therapy
  - Institutionalized patients with severe dementia who have been treated for at least 2 years
  - Have adverse effects
  - Have dementia that has progressed to a point where slowing progression is no longer reasonable
  - Feel the medication is no longer working

Cholinesterase Inhibitors: How to deprescribe?

• Taper off over 2-4 weeks

• Monitor for 1-3 months

• If symptoms worsen, reinitiate therapy

PROTON PUMP INHIBITORS
Proton Pump Inhibitors: Why Deprescribe?

• Limited indications for long-term use

• Potential for drug-drug interactions

• Have been associated with an increase risk for bone fractures, pneumonia, *C. difficile* infections.

• Can decrease absorption of vitamin B12, iron and magnesium

Proton Pump Inhibitors: How to deprescribe?

• Decrease to a lower dose and/or decrease dosing frequency then stop

• Monitor closely for rebound symptoms

• If rebound occurs:
  – Try nonpharmacologic therapy (diet changes, weight loss)
  – Intermittent dosing of antacids or H2RAs

• If symptoms continue for 3-7 days and interfere with daily activities:
  – Test and treat for *H. pylori*
  – Consider return to previous dose

NSAIDS/ASA (>325MG/DAY)
NSAIDs/ASA (>325mg/day): Why Deprescribe?

• Worsen chronic kidney disease (CKD), congestive heart failure (CHF) and blood pressure

• Increase risk of acute kidney injury

• Cause or worsen ulcers

NSAIDs/ASA (>325mg/day): How to deprescribe?

- For osteoarthritis, switch to acetaminophen or stop medications (no taper needed)
- For inflammatory conditions, may need a slow taper to limit pain
- Monitor pain symptoms
- If pain returns and is localized:
  - Consider topical NSAIDs or corticosteroid injections
- If pain returns is severe and/or non-localized
  - Restart at lowest effective dose
  - Consider using a COX-2 inhibitor plus a PPI for patients at risk for GI bleeding

STATINS
Statins: Why Deprescribe?

• Limited evidence for patients >80 years of age

• Older patients are at higher risk for statin-related side effects such as myopathy

• Quality of life is improved in patients with limited life expectancy

• Benefits may continue for 5+ years after discontinuation

Statins: Candidates for deprescribing

- Patients who:
  - Are >80 years of age
  - Using statins for primary prevention and have been taking them for >5 years
  - Have a life expectancy <5 years
  - Are experiencing significant side effects (myopathy)


Statins: How to deprescribe?

• Stop the statin
  – No taper necessary

Antihypertensives: Why Deprescribe?

• Low blood pressure may be associated with increased morbidity and mortality

• Patients with postural hypotension are more likely to fall when being treated for hypertension

• Elderly patients are more sensitive to adverse drug effects
  – Diuretics can cause hypotension and incontinence

Antihypertensives: Candidates for deprescribing

• Patients who:
  – Frail elderly and/or immobile
  – At high fall risk
  – Have confirmed postural hypotension
    • >20mmHg fall in systolic and/or >10mmHg fall in diastolic BP when staining

Antihypertensives: How to deprescribe?

• If blood pressure is below target
  – Reduce dose or number of antihypertension medications
  – Taper by 25% every month for 3-4 months

• Monitor closely

• Initiate lifestyle changes to support medication reduction or cessation

• Reinitiate if needed

BISPHOSPHONATES
Bisphosphonates: Why Deprescribe?

• Benefits may persist long after discontinuation

• Longer treatment may not provide additional benefit
  – Especially in patients with low risk of falls and only non-vertebral fractures

• Oral bisphosphonates can cause upper GI adverse effects

• Increased risk of cardiac arrhythmias in patients who zolendronic acid use for 9 years vs. 6 years

Bisphosphonates: Deprescribing

• Patients with 3-5 years of therapy may be candidates for a 1-2 year “drug holiday”
  – Monitor bone mineral density every 2 years
  – Reinitiate therapy if T-score drops below -2.5

• Patients who should continue therapy:
  – Persistent high risk of fracture after 3-5 years of therapy
    • Very low T-score (-2.5 or below)
  – Suffered a fracture while on therapy
ANTIHYPERGLYCEMIC AGENTS
Antihyperglycemic Agents: Why Deprescribe?

- Increased risk of hypoglycemia which can lead to falls, fractures, and impaired cognition

- Sulfonylureas have limited efficacy after 10 years of therapy due to decreased beta cell function


Antihyperglycemic Agents: Candidates for deprescribing

• Patients:
  – At risk of hypoglycemia
  – At risk for or experiencing adverse effects from antihyperglycemic agents
  – With uncertainty about clinical benefits
    • Frail, dementia, limited life-expectancy

Antihyperglycemic Agents: How to deprescribe?

• Reduce dose or discontinue medication

• Monitor blood sugars daily for 1-2 weeks after each change
  – Up to 12 weeks for TZDs

• If hyperglycemia occurs, return to previous dose or consider starting an agent with lower risk of hypoglycemia

SUMMARY
Take-Home Points

• There are many tools and resources available to assist both providers and patients with deprescribing

• Successful deprescribing plans must involve the patient and caregivers in the decision making process

• When possible, use evidence-based guidelines, algorithms and titration schedules to develop deprescribing plans
QUESTIONS/DISCUSSION